For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Pimozide (sold under the brand name Orap) is an antipsychotic drug of the diphenylbutylpiperidine class. It was discovered at Janssen Pharmaceutica in 1963. It has a high potency compared to chlorpromazine (ratio 50-70:1). On a weight basis it is even more potent than haloperidol. It also has special neurologic indications for Tourette syndrome and resistant tics. The side effects include akathisia, tardive dyskinesia, and, more rarely, neuroleptic malignant syndrome and prolongation of the QT interval.
Scope of the Report:
The global average price of Pimozide is in the increasing trend, from 1.13 USD/Unit in 2013 to 1.19 USD/Unit in 2017. With the situation of global economy, prices will be in increasing trend in the following five years.
The classification of Pimozide includes 1Mg, 2Mg, 4Mg, and the proportion of 2Mg in 2017 is about 53%.
Pimozide is widely used in hospitals, drugstores and other places. The most proportion of Pimozide is used for hospitals in 2017 is 54%.
The worldwide market for Pimozide is expected to grow at a CAGR of roughly -1.1% over the next five years, will reach 11 million US$ in 2024, from 12 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Pimozide in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Teva
- Par Pharmaceutical
- Johnson & Johnson
- Eumedica
- Pharmascience
- Domina Pharmaceuticals
- Aa Pharma
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- 1Mg
- 2Mg
- 4Mg
Market Segment by Applications, can be divided into
- Hospitals
- Drugstores
- Others
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Pimozide product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Pimozide, with price, sales, revenue and global market share of Pimozide in 2017 and 2018.
Chapter 3, the Pimozide competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Pimozide breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Pimozide market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Pimozide sales channel, distributors, customers, research findings and conclusion, appendix and data source.